{
    "nct_id": "NCT05382442",
    "official_title": "A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Histologically proven diagnosis of colorectal adenocarcinoma\n* Part1: Subjects who have not previously received any systemic antitumor therapy and who have previously received neoadjuvant or adjuvant therapy, the first detection of recurrence or metastasis should be â‰¥12 months after the last administration of neoadjuvant or adjuvant therapy\n* Part2: Subjects who have previously received systemic therapy including fluorouracil, oxaliplatin, irinotecan, bevacizumab or anti-EGFR antibodies or could not tolerate or have contraindications to standard treatment\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Measurable disease as defined by RECIST v1.1\n* Adequate hematologic and organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Known MSI-H(Microsatellite-Instability-High) or dMMR(Mismatch Repair-Deficient)\n* Prior treatment with immunotherapy, including immune checkpoint inhibitors , immune checkpoint agonists, immune cell therapy and any treatment targeting tumor immune pathway\n* History of autoimmune disease\n* Prior allogeneic stem cell or solid organ transplantation\n* Positive test for human immunodeficiency virus,Active hepatitis B or hepatitis C\n* Receipt of a live, attenuated vaccine within 30 days prior to randomization, during treatment\n* Pregnancy or lactation\n* Dysphagia",
    "miscellaneous_criteria": ""
}